Prognostic Significance of Tissue Inhibitor of Metalloproteinase-1 in Breast Cancer

Table 4

Clinicopathologic features of the patients included in the TMA analysis.

		Univariate analysis
		Recurrence		Death
		HR	𝑃	HR	𝑃
Number of patients	145
Age at diagnosis
Median	52 years
Range	26–89 years
Recurrence
Events	78 (54%)
Death
Events	61 (42%)
ER status
Positive	90 (62%)	1.41 (0.89–2.24)	0.14	1.89 (1.13–3.14)	0.01
Negative	55 (48%)
HER2 status
Amplified	25 (18%)	0.99 (0.56–1.77)	0.98	0.7 (0.34–1.42)	0.32
Non-amplified	117 (82%)
Grade
3	103 (71%)	1.39 (0.83–2.33)	0.22	1.52 (0.84–2.77)	0.17
1-2	42 (29%)
Stage
I	31 (21%)	0.99 (0.55–1.80)	0.98	1.34 (0.64–2.83)	0.44
IIA/IIB	102 (70%)
IIIA/IIIB	12 (9%)
Cytoplasmic; TIMP-1 score
Low (0, 1+, 2+)	51 (35%)	1.02 (0.65–1.62)	0.92	1.41 (0.83–2.42)	0.21
High (3+)	94 (65%)